Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Takeda Mulls Takeover Bid for Shire
Takeda Pharmaceutical is exploring a possible takeover of London-listed Shire, although no approach has been made so far, the company said on March 28. In a statement, Takeda said that it is “considering making an approach to Shire regarding a…
To read the full story
Related Article
- Grilled by Shareholders, Takeda CEO Seeks Understanding for Shire Deal
June 29, 2018
- Takeda Shareholders Strike Down Dissident Group’s Proposal
June 28, 2018
- Angry Shareholders Say Don’t Make Takeda a Debt-Saddled Company
June 12, 2018
- Takeda’s Founding Family-Backed Shareholders Demand Prior Vote for 1 Trillion Yen-Plus Deals
June 6, 2018
- Takeda Confident It Can Reduce Debt Quickly after Shire Takeover: CEO
May 11, 2018
- Takeda Attracted to Shire’s High Profitability, Rare Disease Pipeline: CEO
May 9, 2018
- Takeda, Shire Reach Preliminary Deal, Extend Takeover Deadline to May 8
April 25, 2018
- Takeda Makes Fifth Pitch for Shire Buyout as Deadline Looms
April 25, 2018
- Takeda Sweetens Bid for Shire, Ups Cash Component
April 23, 2018
- Takeda in Talks with Shire after 3 Buyout Proposals Rejected
April 20, 2018
BUSINESS
- Lunsumio Combo Hits PIII Goal in Follicular Lymphoma: Roche
September 18, 2026
- Padcev-Keytruda Gets CHMP Nod for Expanded MIBC Use
September 18, 2026
- SanBio Eyes October Start for Akuugo Treatment
September 18, 2026
- Toho Unit to Launch Pharma-Wholesaler Payment Service
September 18, 2026
- Astellas Names Marino General Counsel, Compliance Chief
September 18, 2026
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…